The company said it also saw record cash collections in the quarter despite challenges caused by regulatory change.
The company said revenues in its diagnostics business unit rose 62 percent during the quarter.
The company said test volume rose 87 percent to 186,000 during the quarter.
Lifted by a strong flu season, Cobas Liat PCR placements reached 1,500 systems in the US. Globally, year-over-year sales for the point-of-care system grew 262 percent.
The company said it had a large uptick in testing revenues during the quarter, including for its AlloSure kidney transplant test, which was launched in October.
Guidance for 2018 placements of ePlex respiratory testing systems is lower than analysts’ estimates, but the firm communicated remedies for adoption challenges.
On a conference call following the release of the earnings, the firm's CEO guided for lower 2018 ePlex placements than had been expected by analysts.
The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.
Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.
Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.
At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.
The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.
Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.
In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.